Updated Recommendation
A new evidence synthesis was published:2022, Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.
View latest version (2022)Bibliographic Info
Recommendation
Recommended in favor
Strong
Certainty of evidence
Moderate
For adults, adolescents and children, a short-course (one-week) induction regimen with amphotericin B deoxycholate (1.0 mg/kg/day) and flucytosine (100 mg/kg/ day, divided into four doses per day), followed by 1 week of fluconazole (1200 mg/day for adults, 12 mg/kg/day for children and adolescents, up to a maximum dose of 800mg daily), is the preferred option for treating cryptococcal meningitis among people living with HIV
Notes and Remarks
A minimum package of pre-emptive hydration and electrolyte replacement and toxicity monitoring and management should be provided to minimize treatment toxicity during induction phase with amphotericin B containing regimens and flucytosine.
Also Featured In
This recommendation also appears in the following guidelines:
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.